Overview
- The National Health and Medical Research Council issued interim clinical advice on Monday that puberty blockers can be a clinical option for some trans and gender-diverse young people when chosen through shared decision-making.
- The Gender Guidelines Development Committee made a conditional recommendation based on 15 mostly observational studies judged to be low-certainty and noted gaps on fertility and long-term bone health.
- The advice is open for public consultation until 18 January 2027 and will feed into fuller national guidance on gender-affirming care due in 2028.
- Federal Health Minister Mark Butler urged states to consider the NHMRC advice but Queensland and the Northern Territory said they will keep their public-hospital bans and Victoria’s Coalition pledged an immediate review if elected.
- Because the NHMRC guidance is advisory rather than legally binding, implementation will vary across jurisdictions and could directly affect whether young people can access puberty blockers through public health services while further research and political debate continue.